Is Fortress Biotech, Inc. (FBIO) a Buy, Sell, or Hold?
Fortress Biotech, Inc.
NASDAQ:FBIO
$3.73 USD
$0.43 (13.03%)
- Volume
- 1.24M
- Average Volume
- 430.49K
- Market Capitalization
- $123.91M
- P/E Ratio
- 0.97
- Dividend Yield
- 0.00%
- Price Target
- $5.00
- Year High
- $4.53
- Year Low
- $1.77
- Day High
- —
- Day Low
- —
- Payout Ratio
- $0.00
- Current Ratio
- $2.86
Industry, Sector & symbol
| Stock Exchange | NASDAQ |
| CEO | Lindsay Allan Rosenwald |
| Industry | Biotechnology |
| Sector | Healthcare |
| Current Symbol | FBIO |
| CUSIP | 34960Q307 |
| CIK | 0001429260 |
| Web | https://www.fortressbiotech.com |
| Phone | 781 652 4500 |
| Currency | USD |
| Employees | 78 |
| Country | US |
Liquidity
| Debt-to-Equity Ratio | 0.33 |
| Payout Ratio | 0.00 |
| Current Ratio | 2.86 |
| Quick Ratio | 2.77 |
| Cash Ratio | 2.47 |
Sales & Book Value
| Annual Sales | $63.26M |
| Price / Sales | 1.87 |
| Cash Flow | 5.00 |
| Price / Cash Flow | 0.79 |
| Price / Book | 0.73 |
Price Target and Rating
| Average Stock Price Forecast | $5.00 |
| High Stock Price Forecast | $5.00 |
| Low Stock Price Forecast | $5.00 |
| Forecast Upside/Downside | -25.40% |
| Consensus Rating | Buy |
| Rating Score(0-5) | 4 |
| Research Coverage | 6 Analysts |
Profitability
| EPS (Most Recent Fiscal Year) | $-0.0674 |
| Trailing P/E Ratio | 0.97 |
| PEG Ratio | 0.00 |
| P/E Growth | 0.00 |
| Net Income | $6.82M |
| Net Margin | 193.12% |
| Pretax Margin | 201.45% |
| Return on Equity | 163.88% |
| Return on Assets | 35.80% |
Financials Score
| AltmanZ Score | 0.13 |
| Piotroski Score | 6.00 |
| Working Capital | 192.09M |
| Total Assets | 356.87M |
| Ebit | 142.85M |
| Market Cap | 109.62M |
| Total Liabilities | 154.5M |
Poll Results
About Fortress Biotech, Inc. (NASDAQ:FBIO) Stock
Fortress Biotech, Inc. operates as a biopharmaceutical firm dedicated to the development and commercialization of a diverse range of pharmaceutical and biotechnology products. The company currently offers a portfolio of dermatological treatments. These include Ximino and Targadox, both formulated to address various forms of acne (ranging from moderate-to-severe inflammatory lesions to severe cases). Other products in this segment are Exelderm cream for fungal skin infections like ringworm and jock itch, Ceracade for dry skin conditions, Luxamend for wound care, and Accutane capsules for particularly severe, stubborn nodular acne. Its pipeline features several promising late-stage drug candidates, targeting a diverse range of medical needs. These include intravenous Tramadol for acute post- ... operative pain, CUTX-101 (an injection for Menkes disease), MB-107 and MB-207 for X-linked severe combined immunodeficiency, Cosibelimab for metastatic cancers, CK-101 for non-small cell lung cancer characterized by EGFR mutations, CAEL-101 for amyloid light chain (AL) amyloidosis, the Triplex vaccine for cytomegalovirus, and CEVA101 for critical traumatic brain injuries in adults and children. Furthermore, its earlier-stage research encompasses various investigational treatments such as MB-102 for blastic plasmacytoid dendritic cell neoplasm, MB-101 for glioblastoma, MB-104 for multiple myeloma and light chain amyloidosis, MB-106 for B-cell non-Hodgkin lymphoma, MB-103 for glioblastoma and metastatic breast cancer to the brain, MB-108, MB-105 for prostate and pancreatic malignancies, and BAER-101. In the preclinical phase, Fortress Biotech is exploring an array of novel therapeutic approaches. These comprise AAV-ATP7A and AVTS-001 (both gene-based therapies), the CK-103 BET inhibitor, CEVA-D and CEVA-102, CK-302 (an antibody targeting GITR), CK-303 (an antibody against CAIX), ConVax, and the ONCOlogues oligonucleotide platform. The company also actively engages in collaborative ventures with universities, research institutions, and other pharmaceutical organizations. Originally established in 2006, the entity operated as Coronado Biosciences, Inc. before rebranding as Fortress Biotech, Inc. in April 2015. Its corporate headquarters are situated in Bay Harbor Island, New York.
Fortress Biotech: Is It Time To Pay The Deferred Preferred Stock Dividends?
2026-05-29 17:20:13
Fortress Biotech now holds $256 million in cash and only $39 million in debt, establishing a fortress balance sheet. FBIO's recent windfall from the Menkes disease drug sale positions it to easily pay $16 million in deferred FBIOP preferred dividends. FBIOP dividends, deferred for nearly two years, could total $4.69 per share if paid by June 15, 2026, benefiting significant insider holders.
Journey Medical Corporation to Participate in A.G.P.'s Annual Virtual Healthcare Conference
2026-05-19 16:45:00
SCOTTSDALE, Ariz., May 19, 2026 (GLOBE NEWSWIRE) -- Journey Medical Corporation (Nasdaq: DERM) (“Journey Medical,” “the Company,” “we” or “our”), a commercial-stage pharmaceutical company focused on developing, selling and marketing FDA-approved prescription pharmaceutical products for the treatment of dermatological conditions, today announced that Claude Maraoui, Co-Founder, President and Chief Executive Officer, will participate in a fireside chat at A.G.P.'s Annual Virtual Healthcare Conference, taking place on Wednesday, May 20, 2026. The fireside chat is scheduled to begin at 5:00pm ET.
Fortress Biotech to Participate in A.G.P.'s Annual Virtual Healthcare Conference
2026-05-18 08:30:00
MIAMI, May 18, 2026 (GLOBE NEWSWIRE) -- Fortress Biotech, Inc. (Nasdaq: FBIO) (“Fortress”), an innovative biopharmaceutical company focused on acquiring and advancing assets to enhance long-term value for shareholders through product revenue, equity holdings and dividend and royalty income, today announced that Lindsay A. Rosenwald, M.D., Chairman, President and Chief Executive Officer, will participate in a fireside chat at A.G.P.'s Annual Virtual Healthcare Conference, taking place on Wednesday, May 20, 2026. The fireside chat is scheduled to begin at 12:20pm ET.
Fortress Biotech Reports First Quarter 2026 Financial Results and Recent Corporate Highlights
2026-05-14 16:10:00
ZYCUBO® approved by FDA to treat Menkes disease in the United States; Fortress subsidiary Cyprium Therapeutics closed the sale of its Rare Pediatric Disease Priority Review Voucher (PRV) for $205 million
2026-05-13 16:01:00
Total revenues for the first quarter ended March 31, 2026 increased 21% year-over-year to $16.0 million Emrosi ® revenues were $6.3 million in the first quarter ended March 31, 2026 Cash position increased to $27 million, driven by strong financial performance Company to hold conference call today at 4:30 p.m. ET SCOTTSDALE, Ariz.
Journey Medical Corporation to Announce First Quarter 2026 Financial Results on May 13, 2026
2026-05-06 16:01:00
Company to host conference call to discuss financial results and provide a corporate update on May 13, 2026 at 4:30 p.m. ET Company to host conference call to discuss financial results and provide a corporate update on May 13, 2026 at 4:30 p.m. ET
Fortress Biotech to Participate in the H.C. Wainwright 2nd Annual Royalty Company Virtual Conference
2026-05-04 08:30:00
MIAMI, May 04, 2026 (GLOBE NEWSWIRE) -- Fortress Biotech, Inc. (Nasdaq: FBIO) (“Fortress”), an innovative biopharmaceutical company focused on acquiring and advancing assets to enhance long-term value for shareholders through product revenue, equity holdings and dividend and royalty income, today announced that Lindsay A. Rosenwald, M.D., Chairman, President and Chief Executive Officer, will participate in a fireside chat at the H.C. Wainwright 2nd Annual Royalty Company Virtual Conference, taking place on Wednesday, May 6, 2026. The fireside chat is scheduled to begin at 12:30pm ET.
Journey Medical Corporation Secures Contract with Third Major GPO for Emrosi™
2026-04-21 08:30:00
Payer access for Emrosi™ expanded from approximately 100 million commercial lives to over 150 million commercial lives as of April 1, 2026 Payer access for Emrosi™ expanded from approximately 100 million commercial lives to over 150 million commercial lives as of April 1, 2026
Frequently Asked Questions
-
What is the current Fortress Biotech, Inc. (FBIO) stock price?
-
Fortress Biotech, Inc.(NASDAQ:FBIO) stock price is $3.73 in the last trading session. During the trading session, FBIO stock reached the peak price of $4.53 while $1.77 was the lowest point it dropped to. The percentage change in FBIO stock occurred in the recent session was 13.03% while the dollar amount for the price change in FBIO stock was $0.43.
-
FBIO's industry and sector of operation?
-
The NASDAQ listed FBIO is part of Biotechnology industry that operates in the broader Healthcare sector.
-
Who are the executives of FBIO?
-
Xiaoqin Lu | Chief Strategy Officer
Lindsay Allan Rosenwald | Executive Chairman, President & Chief Executive Officer
Samuel Berry | General Counsel & Corporate Secretary
David Jin | Chief Financial Officer & Head of Corporate Development
Michael S. Weiss | Executive Vice Chairman of Strategic Development & Director -
How many employees does FBIO have?
-
Number of FBIO employees currently stands at 78. FBIO operates from 1111 Kane Concourse, Bay Harbor Islands, FL 33154, US.
-
Link for FBIO official website?
-
Official Website of FBIO is: https://www.fortressbiotech.com
-
How do I contact FBIO?
-
FBIO could be contacted at phone #781 652 4500 and can also be accessed through its website. FBIO operates from 1111 Kane Concourse, Bay Harbor Islands, FL 33154, US.
-
How many shares of FBIO are traded daily?
-
The average number of FBIO shares traded daily for last 3 months was 430.49K.
-
What is the market cap of FBIO currently?
-
The market value of FBIO currently stands at $123.91M with its latest stock price at $3.73